Tag

Leqembi

All articles tagged with #leqembi

health-and-wellness1 month ago•4 min saved

Early Alzheimer’s therapies slow progression, easing a caregiver’s load

A Oklahoma City woman relocates to care for her father, diagnosed with mild cognitive impairment due to Alzheimer's, and discovers that early treatment with infusions like Leqembi has kept his condition largely stable for about 18 months. The experience offers relief and time for the family to plan, even as experts caution that such therapies slow decline rather than cure the disease and stress the importance of early detection and caregiver resources.

via USA Today|

#alzheimers-disease #caregiving #early-detection

health1 year ago•3 min saved

Israel's New Alzheimer’s Treatment Available Only to the Wealthy

Israel is pioneering new Alzheimer's treatments like Leqembi, which can slow disease progression, but access is limited to the wealthy due to high costs not covered by public health, raising concerns about inequality in healthcare.

via Ynetnews|

#alzheimers-treatment #cost #health

health1 year ago•4 min saved

Leqembi Endorsed for Early Alzheimer's Therapy

The European Medicines Agency's human medicines committee has recommended Leqembi (lecanemab) for treating early Alzheimer's disease in patients with one or no copies of the ApoE4 gene, due to a lower risk of amyloid-related imaging abnormalities (ARIA). This decision follows a re-examination of data showing Leqembi's benefits in slowing cognitive decline outweigh its risks in this restricted population. The recommendation includes safety measures like MRI monitoring and a controlled access programme to mitigate ARIA risks. The decision now awaits approval from the European Commission.

via European Medicines Agency ||

#alzheimers #apoe4 #aria

health-medicine2 years ago•5 min saved

"Slow Start for 1st Drug in Slowing Alzheimer's Progression"

The first drug shown to slow Alzheimer’s disease, Leqembi, has had a slow start in the U.S. market, with lagging sales, delayed hospital adoption, and insurance coverage rejections. While offering hope for patients, the drug's limited impact and potential side effects have led to cautious uptake. Challenges include setting up systems for drug delivery, understanding coverage, and identifying eligible patients. Despite these hurdles, the drug's maker, Eisai, remains optimistic about its potential and is working on an injectable version and seeking approval for an easier-to-use form.

via AL.com|

#alzheimers #drug-sales #health-medicine

health2 years ago•4 min saved

"Challenges in the Adoption of the First Alzheimer's-Slowing Drug"

The first drug shown to slow Alzheimer’s disease, Leqembi, has faced slow adoption due to limited impact, potential side effects, and challenges in setting up systems for delivering the drug. Major hospital systems have taken months to start using it, some insurers have rejected coverage, and patients may hesitate due to the drug's subtle delay in disease progression and potential side effects. While the drug's maker, Eisai, is working to improve access and coverage, doctors emphasize the need for improved diagnosis and quicker treatment initiation for Alzheimer's patients.

via The Associated Press|

#alzheimers #drug-approval #health

healthcare2 years ago•3 min saved

Eisai Anticipates Significant Growth with China Alzheimer's Launch

Eisai plans to launch its Alzheimer's drug Leqembi to 1,500 patients in China this year, with expectations of significant growth in 2025 as more convenient blood tests become available. Eli Lilly is also developing a similar treatment and has filed for approval in China. The introduction of blood tests is expected to increase interest in the treatment. However, China's healthcare system is currently ill-prepared to provide timely access to Alzheimer's treatments, with limited diagnosis and treatment rates and a lack of specialty care in rural areas.

via Reuters|

#alzheimers #china #eisai

health-pharmaceuticals2 years ago•2 min saved

"Biogen Shifts Focus Away from Aduhelm, Explores Alternative Alzheimer's Treatments"

Biogen is discontinuing its controversial Alzheimer's drug Aduhelm to focus on other treatments, including its blockbuster drug Leqembi, which was developed with Japan's Eisai and approved in 2023. The decision comes after concerns about the risks of Aduhelm outweighing its benefits, leading Medicare to significantly limit coverage of the drug. Despite discontinuing Aduhelm, Biogen aims to build a leading franchise addressing the multiple pathologies of Alzheimer's disease and patient needs.

via Fox Business|

#aduhelm #alzheimers #biogen

health-pharmaceuticals2 years ago•2 min saved

"Biogen Pulls Aduhelm: Shifting Focus to Experimental Alzheimer's Treatments"

Biogen has withdrawn its controversial Alzheimer's drug, Aduhelm, from the market following criticism and irregularities in the approval process by the US FDA. The drug's accelerated approval was highly contentious, and its high price of $56,000 a year for patients was deemed unjustifiably high. Biogen will focus on its newer Alzheimer's medicine, Leqembi, which was fully approved last year. Alzheimer's is the most common form of dementia, affecting more than one in nine people over 65.

via ScienceAlert|

#aduhelm #alzheimers #biogen

health-pharmaceuticals2 years ago•2 min saved

"Biogen's Decision to Discontinue Aduhelm: Impact on Alzheimer's Treatment"

Biogen will discontinue the sale of its Alzheimer's drug Aduhelm and halt the study needed for full FDA approval, shifting focus to other treatments. The drug, initially anticipated to be a blockbuster, faced challenges with limited evidence of efficacy and insurance coverage restrictions. Biogen will support the sale of another Alzheimer's treatment, Leqembi, which received full FDA approval. The company will incur a charge of about $60 million for shutting down the Aduhelm program, while patients may soon have another treatment option pending FDA review of a potential drug from Eli Lilly and Co.

via The Associated Press|

#aduhelm #alzheimers #biogen

health2 years ago•6 min saved

"Portland Man Joins Promising Alzheimer's Drug Trial"

Ralph Carmona, a Portland man diagnosed with Alzheimer's, participated in a clinical trial for a new drug called Leqembi, which has been approved by the FDA. The drug showed a 27% average slowing of the disease's progression over 18 months. Carmona's positive response, combined with a healthy lifestyle, has led to a good quality of life. Leqembi is now available to the general population, offering hope for Alzheimer's patients. Other drugs targeting Alzheimer's are also showing promising results, and efforts to accelerate Alzheimer's research are underway.

via Press Herald|

#alzheimers #clinical-trial #fda

healthcare2 years ago•5 min saved

Insurers, including Arkansas Blue Cross and Blue Shield, refuse coverage for groundbreaking Alzheimer's drug

Arkansas Blue Cross and Blue Shield, the largest health insurance company in Arkansas, has decided not to cover the Alzheimer's drug Leqembi, citing insufficient evidence of its effectiveness and concerns about its risks. The decision also applies to the health plans covering state and public school employees. The drug, which costs $26,500 a year plus additional clinic administration fees, became the first to win full approval from the FDA for slowing the progression of Alzheimer's. Medicare, the U.S. Veterans Health Administration, Arkansas' Medicaid program, and United Healthcare's standard commercial plans have opted to cover the drug. Advocates are urging insurers to reconsider their coverage decisions.

via Northwest Arkansas Democrat-Gazette|

#alzheimers-disease #arkansas-blue-cross-and-blue-shield #drug-effectiveness

healthcare2 years ago•5 min saved

Insurers Reject Coverage for Alzheimer's Drug, Including Arkansas Blue Cross and Blue Shield

Arkansas Blue Cross and Blue Shield, the largest health insurance company in Arkansas, has decided not to cover the Alzheimer's drug Leqembi, citing insufficient evidence of its effectiveness and concerns about its risks. The health plans covering state and public school employees in Arkansas have also opted not to cover the drug. Leqembi, the first drug approved by the FDA to slow the progression of Alzheimer's, comes with a high price tag of $26,500 per year, plus additional costs for administration. Other insurers, including Medicare, the U.S. Veterans Health Administration, and Arkansas' Medicaid program, will cover the drug.

via Arkansas Online|

#alzheimers-disease #arkansas-blue-cross-and-blue-shield #drug-effectiveness

health2 years ago•3 min saved

"Leqembi: A Promising Drug for Slowing Alzheimer's Progression, but Not a Cure"

The U.S. FDA has granted traditional approval for Leqembi (lecanemab), a new drug for the treatment of early Alzheimer's disease. Leqembi is a monoclonal antibody that slows the progression of symptoms by targeting the amyloid protein found in the brains of Alzheimer's patients. However, the drug is only indicated for individuals with proven amyloid protein in the brain and early Alzheimer's or mild cognitive impairment. It has shown some success in reducing amyloid protein deposition but has only modestly slowed the progression of the disease. Screening for Alzheimer's with this drug is not a high priority, and other lifestyle interventions such as diet, exercise, and cognitive training may be more beneficial in reducing dementia risk.

via OregonLive|

#alzheimers-disease #amyloid-protein #early-treatment

health2 years ago•1 min saved

"Breakthrough Alzheimer's Treatment Leqembi Receives Approval in Japan"

Japan's health ministry has approved the Alzheimer's treatment Leqembi, developed by Eisai and Biogen, making it the second country after the United States to clear its use. Leqembi is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of Alzheimer's patients and is the first treatment shown to slow the progression of the disease in the earlier stages. Eisai will conduct a post-marketing special use results survey to collect data on patients administered with Leqembi. The drug will be co-promoted by Eisai and Biogen in Japan.

via Reuters|

#alzheimers-treatment #biogen #eisai

health3 years ago•0 min saved

"Promising Alzheimer's Drug Sparks Optimism and Uncertainty"

The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer's and mild cognitive impairment, and Medicare has agreed to cover the therapy. Medical centers are working to establish policies and procedures for providing the medication to patients, potentially by the end of summer or early autumn. While there is hope for families and other promising therapies, medical providers remain cautious, recognizing that this is just the first step in developing treatments for complex neurodegenerative diseases.

via Endpoints News|

#alzheimers #disease-modifying-treatment #health